CP-690-550 Ointment For Chronic Plaque Psoriasis

Completed · Phase 2

Conditions studied: Psoriasis

In brief

The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.

Key facts

Study ID

NCT01246583

Run by

Pfizer

People needed

71

Starts

2011-02-16

Expected to finish

2011-11-29

Last updated by the study team

2021-01-11

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of at least 6 months;
• A target plaque of at least 9 sq. cm.

You may not qualify if…

• Demonstrates "rebound" or "flare" of chronic plaque psoriasis;
• Non plaque form of psoriasis;
• Currently have or history of psoriatic arthritis;
• Current drug induced psoriasis;
• Currently on systemic therapy or was on systemic therapy for psoriasis within the previous 6 months;
• Currently on phototherapy for psoriasis or was on phototherapy within the previous 3 months

Where it is running

• Horizon Research Group, Inc. — Mobile, Alabama, United States
• Dermatology Research Associates — Los Angeles, California, United States
• Expresscare Medical — Los Angeles, California, United States
• Park Avenue Dermatology, PA — Orange Park, Florida, United States
• Skin Specialists, PC — Omaha, Nebraska, United States
• Academic Dermatology Associates — Albuquerque, New Mexico, United States
• Health Concepts — Rapid City, South Dakota, United States
• Modern Research Associates, PLLC — Dallas, Texas, United States
• K.Papp Clinical Research Inc. — Waterloo, Ontario, Canada
• Innovaderm Research Inc — Montreal, Quebec, Canada
• Siena Medical Research — Montreal, Quebec, Canada
• Centre de Recherche Dermatologique du Quebec metropolitain — Québec, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.